Lenalidomide (Revlimid), Adriamycin and Dexamethasone (RAD)as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance - A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myeloma (DSMM XII).

Trial Profile

Lenalidomide (Revlimid), Adriamycin and Dexamethasone (RAD)as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance - A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myeloma (DSMM XII).

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2015

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone; Doxorubicin; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association (n = 60).
    • 17 Apr 2013 New source identified and integrated (German Clinical Trials Register; DRKS00003749).
    • 06 Nov 2012 Planned number of patients changed from 146 to 190.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top